Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage ...

Fintel reports that on November 18, 2024, Piper Sandler upgraded their outlook for Aclaris Therapeutics (NasdaqGS:ACRS) from ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

Jefferies analyst Roger Song upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of $7.00. Don't Miss our Black Friday Offers: Roger Song’s ...

BTIG analyst Julian Harrison upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...

Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first ...